$0.5900
At close: Apr 23, 10:10 AM EDT
Comments
Loading...
Helix BioPharma Analyst Ratings and Price Targets | OTC:HBPCF | Benzinga
Helix BioPharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Helix BioPharma Corp from these most-recent analyst ratings.
Analyst Ratings for Helix BioPharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Helix BioPharma (HBPCF) stock?
There is no price target for Helix BioPharma
What is the most recent analyst rating for Helix BioPharma (HBPCF)?
There is no analyst for Helix BioPharma
When was the last upgrade for Helix BioPharma (HBPCF)?
There is no last upgrade for Helix BioPharma
When was the last downgrade for Helix BioPharma (HBPCF)?
There is no last downgrade for Helix BioPharma.
When is the next analyst rating going to be posted or updated for Helix BioPharma (HBPCF)?
There is no next analyst rating for Helix BioPharma.
Is the Analyst Rating Helix BioPharma (HBPCF) correct?
There is no next analyst rating for Helix BioPharma.
Browse analyst ratings and price targets on all stocks.
